Equities analysts expect Puma Biotechnology Inc (NASDAQ:PBYI) to post sales of $69.32 million for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Puma Biotechnology’s earnings, with estimates ranging from $64.63 million to $74.00 million. The company is scheduled to report its next quarterly earnings report on Wednesday, May 9th.
On average, analysts expect that Puma Biotechnology will report full-year sales of $69.32 million for the current financial year, with estimates ranging from $235.00 million to $235.73 million. For the next financial year, analysts expect that the business will post sales of $474.61 million per share, with estimates ranging from $427.11 million to $522.10 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research firms that that provide coverage for Puma Biotechnology.
Puma Biotechnology (NASDAQ:PBYI) last issued its quarterly earnings results on Thursday, March 1st. The biopharmaceutical company reported ($1.71) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.98) by $0.27. The firm had revenue of $21.60 million during the quarter, compared to analyst estimates of $20.83 million. During the same period in the prior year, the firm earned ($1.22) earnings per share.
A number of brokerages have recently issued reports on PBYI. JPMorgan Chase lowered their price target on Puma Biotechnology from $138.00 to $91.00 and set a “buy” rating on the stock in a research note on Wednesday, January 24th. Stifel Nicolaus set a $95.00 price target on Puma Biotechnology and gave the stock a “buy” rating in a research note on Friday, March 9th. Royal Bank of Canada lowered their price target on Puma Biotechnology to $77.00 and set a “sector perform” rating on the stock in a research note on Wednesday, January 24th. BidaskClub lowered Puma Biotechnology from a “buy” rating to a “hold” rating in a research note on Friday, January 26th. Finally, Cowen lowered Puma Biotechnology from an “outperform” rating to a “market perform” rating and lowered their price target for the stock from $123.00 to $68.00 in a research note on Wednesday, January 24th. One analyst has rated the stock with a sell rating, four have given a hold rating and seven have assigned a buy rating to the company. Puma Biotechnology presently has an average rating of “Buy” and an average target price of $103.11.
In related news, SVP Richard Paul Bryce sold 1,860 shares of Puma Biotechnology stock in a transaction that occurred on Monday, January 22nd. The stock was sold at an average price of $92.75, for a total transaction of $172,515.00. Following the transaction, the senior vice president now owns 25,379 shares in the company, valued at $2,353,902.25. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Alan H. Auerbach sold 10,692 shares of Puma Biotechnology stock in a transaction that occurred on Monday, January 22nd. The stock was sold at an average price of $92.75, for a total value of $991,683.00. Following the transaction, the insider now owns 4,155,931 shares in the company, valued at approximately $385,462,600.25. The disclosure for this sale can be found here. Company insiders own 21.10% of the company’s stock.
A number of institutional investors have recently made changes to their positions in PBYI. First Republic Investment Management Inc. purchased a new stake in Puma Biotechnology in the fourth quarter valued at $208,000. Sei Investments Co. purchased a new stake in Puma Biotechnology in the third quarter valued at $256,000. Jafra Capital Management LP purchased a new stake in Puma Biotechnology in the fourth quarter valued at $257,000. SG Americas Securities LLC purchased a new stake in Puma Biotechnology in the third quarter valued at $315,000. Finally, Brown Advisory Inc. purchased a new stake in Puma Biotechnology in the third quarter valued at $320,000. Hedge funds and other institutional investors own 95.95% of the company’s stock.
Shares of NASDAQ:PBYI opened at $64.10 on Tuesday. The company has a current ratio of 1.82, a quick ratio of 1.79 and a debt-to-equity ratio of 0.91. The company has a market capitalization of $2,368.80, a PE ratio of -8.17 and a beta of 0.15. Puma Biotechnology has a 1 year low of $28.35 and a 1 year high of $136.90.
ILLEGAL ACTIVITY NOTICE: “Zacks: Analysts Anticipate Puma Biotechnology Inc (PBYI) Will Announce Quarterly Sales of $69.32 Million” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece on another domain, it was copied illegally and republished in violation of United States & international copyright & trademark law. The correct version of this piece can be accessed at https://www.dispatchtribunal.com/2018/04/10/zacks-analysts-anticipate-puma-biotechnology-inc-pbyi-will-announce-quarterly-sales-of-69-32-million.html.
About Puma Biotechnology
Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.
Get a free copy of the Zacks research report on Puma Biotechnology (PBYI)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.